Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex®) in people with multiple sclerosis: a new approach

Table 4 Analysis of Efficacy adjusting for the three most frequent Nervous System Disorder AEs – summary of ANOVA

	P-values
Source	Model 1	Model 2	Model 3	Model 4
Baseline severity (BS)				<0.0001
Study (ST)				0.15
Adverse event (AE)				0.49
Treatment group (TG)				0.033
AE*ST	0.008	0.011	0.010	0.017
TG*AE	0.15	0.13	0.13
TG*ST	0.80	0.79
TGAEST	0.69
Estimated effect of AE occurrence on spasticity NRS (95% CI)	Previous users:		−1.08 (−1.35 to −0.82)
	No previous use:		−1.20 (−1.38 to −1.01)
	Estimated difference:		−0.11 (−0.44 to 0.21)

ISSN: 1745-6215